Commentary · 21 Feb 2026
Conference abstractPublished 15 Aug 2011
Cancer-Relevant Functions of the Plasma Membrane Receptor for Thyroid Hormone Analogues
Ordway Research Institute and Albany College of Pharmacy and Health Sciences, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Integrin Ã?±vÃ?²3 is a heterodimeric structural protein of the plasma membrane that contains a high affinity receptor for thyroid hormone. Functions of this receptor are wholly distinct from those of the classical nuclear receptor (TR) for thyroid hormone. The hormone receptor on Ã?±vÃ?²3 enables L-thyroxine (T4) and 3, 5, 3âÂ?Â?-triiodo-L-thyronine (T3) to stimulate cancer cell proliferation and angiogenesis. A deaminated derivative of T4, tetraiodothyroacetic acid (tetrac), blocks binding and proliferative actions of T4 and T3 at the Ã?±vÃ?²3 receptor; tetrac also has anti-proliferative actions at the thyroid hormone receptor in the absence of T4 and T3. Structure-activity relationships of hormone analogues at the receptor have been computer-modeled and indicate the receptor includes a site (S1) that binds T3 and a site (S2) for which both T4 and T3 are ligands. Tetrac acts at both S1 and S2. Cell proliferation is modulated from the S2 site. Tetrac has been re-formulated as a nanoparticle (nanotetrac) that acts exclusively at the Ã?±vÃ?²3 receptor and does not enter cells. Nanotetrac 1) disorders expression of genes in multiple cancer cell survival pathways 2) blocks human cancer cell proliferation in vitro and in tumor xenografts and 3) inhibits the pro-angiogenic actions in vitro of VEGF, bFGF and other growth factors. Nanotetrac radiosensitizes cancer cells by inhibiting repair of double-strand DNA breaks. Thus, the receptor described on integrin Ã?±vÃ?²3 for T4 and T3 provides insight into tumor cell and vascular cell biology and tetrac formulations offer a novel, disabling effects on multiple cancer cell defense pathways.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Paul J. Davis”
- BylineArticles whose byline prints “Hung-Yun Lin”
- BylineArticles whose byline prints “Vivian Cody”
- BylineArticles whose byline prints “Faith B. Davis”
- BylineArticles whose byline prints “Aleck Hercbergs”
- BylineArticles whose byline prints “Shaker A. Mousa”
